Assuming that the expression levels of TG2 in the tumor or in surrounding tissues (notably in stroma) [62] correlate positively to a mesenchymal phenotype, promoting EMT as a consequence of drug-resistance [63], in this study, we have analyzed the relationships between TG2 activity and the motility of breast tumor cells. This evidence concerns the gene TGM2 and breast neoplasm.